Ghrelin increases intake of rewarding food in rodents by Egecioglu, Emil et al.
Ghrelin increases intake of rewarding food in rodents
Emil Egecioglu
1, Elisabet Jerlhag
2, Nicolas Salomé
1, Karolina P. Skibicka
1, David Haage
3,
Mohammad Bohlooly-Y
4, Daniel Andersson
2, Mikael Bjursell
4, Daniel Perrissoud
5,
Jörgen A. Engel
2 & Suzanne L. Dickson
1
Department of Physiology/Endocrinology1 and Department of Pharmacology2, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the
University of Gothenburg, Sweden, Department of Integrative Medical Biology, Section for Physiology, Umeå University, Sweden3, AstraZeneca R&D Mölndal,
Sweden4 and ÆternaZentaris, Frankfurt, Germany5
ABSTRACTadb_216 304..311
We investigated whether ghrelin action at the level of the ventral tegmental area (VTA), a key node in the mesolimbic
reward system, is important for the rewarding and motivational aspects of the consumption of rewarding/palatable
food. Mice with a disrupted gene encoding the ghrelin receptor (GHS-R1A) and rats treated peripherally with a
GHS-R1Aantagonistbothshowsuppressedintakeof rewardingfoodinafreechoice(chow/rewardingfood)paradigm.
Moreover, accumbal dopamine release induced by rewarding food was absent in GHS-R1A knockout mice. Acute
bilateralintra-VTAadministrationof ghrelinincreased1-hourconsumptionof rewardingfoodbutnotstandardchow.
In comparison with sham rats, VTA-lesioned rats had normal intracerebroventricular ghrelin-induced chow intake,
although both intake of and time spent exploring rewarding food was decreased. Finally, the ability of rewarding food
toconditionaplacepreferencewassuppressedbytheGHS-R1Aantagonistinrats.Ourdatasupportthehypothesisthat
central ghrelin signaling at the level of the VTA is important for the incentive value of rewarding food.
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INTRODUCTION
Ghrelin, a gastric-derived peptide (Kojima et al. 1999),
increases food intake (Wren et al. 2000) and has pro-
obesity effects (Tschöp, Smiley & Heiman 2000). Indeed,
thepreprandialriseincirculatingghrelinlevelsinhuman
subjectsthatcorrelateswithhungerscoreshasbeenused
tosuggestaroleinhungerandmealinitiation(Cummings
et al.2001).Theseeffectsareexerted,atleastinpart,atthe
level of the hypothalamus (Tschöp et al. 2000; Cowley
et al. 2003), especially the arcuate nucleus where the
ghrelin receptor, growth hormone secretagogue receptor
1A (GHS-R1A), is expressed in abundance (Howard et al.
1996; Guan et al. 1997). GHS-R1A is also present in teg-
mentalareasimplicatedinfoodrewardandaddiction,the
ventral tegmental area (VTA) and the laterodorsal teg-
mental area (Guan et al. 1997). Indeed, recently we dem-
onstrated that ghrelin injection intracerebroventricular
(i.c.v.) or into the VTA or laterodorsal tegmental area
stimulates parameters associated with reward-seeking
behavior (Jerlhag et al. 2006, 2007, 2008), a ﬁnding
conﬁrmedandextendedbyothers(Abizaidet al.2006).In
addition,humanfunctionalimagingstudieshaverecently
shown that peripheral ghrelin administration modulates
brain responses to food images in several areas associated
with reward (Malik et al. 2008).
The mesolimbic dopamine projections, originating
from neuronal cell populations in the VTA and terminat-
ing in the ventral striatum and the prefrontal cortex, are
linked to anticipatory, appetitive or approach phases of
motivated behavior and are important for anticipatory
food reward and food-seeking behavior (Richardson &
Gratton 1998; Bassareo & Di Chiara 1999). Activation of
these dopamine projections is also elicited by ingestion of
rewarding/palatable foods as well as by other rewards,
both natural (e.g. sex) and artiﬁcial (e.g. drugs of abuse)
(Berridge & Robinson 1998). Furthermore, feeding
behavior and food-reinforced responses can be disrupted
bypharmacologicinterferencewiththedopaminesystem
(Barzaghi et al. 1973).
Given the role for the mesolimbic dopamine system in
incentive processes related to natural rewards such as
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system is a target for ghrelin, we set out to demonstrate
that ghrelin increases food reward and conversely, that
food reward is suppressed in genetic and pharmacologic
models of suppressed ghrelin signaling.Thus, we investi-
gated whether (1) intra-VTA ghrelin injection increases
the intake of rewarding food and/or normal chow; (2)
GHS-R1A knockout (KO) mice and GHS-R1A antagonist-
treated rats show reduced preference for rewarding food;
(3) accumbal dopamine release induced by rewarding
food is suppressed in GHS-R1A KO mice; (4) VTA lesion
disrupts food intake and the motivation to eat palatable
food following ghrelin treatment; and (5) the ability of
rewarding food to condition a place preference is sup-
pressed by GHS-R1A antagonists.
MATERIALS AND METHODS
Animals
AdultmaleNMRImice(25–35 gBWt,B&K,Sollentuna,
Sweden) were used for locomotor activity and feeding
experiments following intra-VTA injections of ghrelin.
Female GHS-R1A KO and wild-type littermate mice (20–
25 gBWt,generationof GHS-R1AKO:seesupplementary
Fig. S1; details provided at the end) were used for food
preference experiments. For microdialysis experiments,
male GHS-R1A KO and wild-type littermate mice were
used.
Adult (200–220 g BWt) Sprague-Dawley rats (B & K)
were used for food preference and conditioned place pref-
erence (CPP) studies. Standard chow (Harlan Teklad;
Norfolk, England) and water were available ad libitum
unlessotherwisestated.Theanimalroomwasmaintained
on a 12/12 hour light/dark cycle, at 20°C and 50%
humidity. The local Ethics Committee for Animal Experi-
ments (Gothenburg, Sweden) approved all procedures.
Drugs
Acetylated rat ghrelin (Bionuclear, Bromma, Sweden)
was dissolved in vehicle solution (Ringer, Merck KGaA,
Darmstadt, Germany) and administered bilaterally into
the VTA at a dose of 2 mg/mouse. This dose has been
shown to activate the mesolimbic dopamine system
(Jerlhaget al.2006).Acetylatedhumanghrelin(giftfrom
Rose Pharma A/S, Copenhagen, Denmark) dissolved in
salinewasadministeredasasinglei.c.v.injection(1 mg)in
theVTAlesionstudiesinrats.Thedoseof JMV2959(Æter-
naZentaris), a GHS-R1A antagonist (Moulin et al. 2007),
was dissolved in saline and administered i.p. to rats at a
dose of 12 mg/kg per day in the food preference experi-
ment and at a dose of 1 mg/kg in the CPP experiment.
Surgery
NMRImicewereimplantedwithbilateralguidecannulae
into the VTA and rats into the lateral ventricle using ste-
riotaxic co-ordinates as described previously (Jerlhag
et al. 2007; Salomé et al. 2009). In rats coordinates used
for VTA lesion relative to bregma were: 6.0 mm posterior,
0.6 mm lateral and 8.4 mm below the surface of the
brain(Paxinos&Watson1986).Bilaterallesionsinvolved
ibotenic acid injection (0.06 M in saline, 200 nl, Sigma).
Sham animals received saline only. Wild-type littermate
controls and GHS-R1A KO mice were implanted with a
unilateral microdialysis probe (Waters et al. 1993) posi-
tioned in the N.Acc. for measurement of extracellular
dopamine levels as described previously (Jerlhag et al.
2006). All animals were individually housed following
implantation of injection cannulae or microdialysis
probes.
Food intake/preference measurements in genetic and
pharmacologic models of suppressed ghrelin signaling
Individually housed wild-type and GHS-R1A KO mice
were put on a free choice ad libitum feeding paradigm,
consisting of chow and peanut butter for 7 days. Indi-
vidually housed rats were given a free choice of ad libitum
chow and Ensure® chocolate drink for 10 days. This pal-
atable drink induces obesity in rats (Levin & Dunn-
Meynell 2002). On day 4, rats received i.p. injections of
JMV2959 or saline. Animals that did not spontaneously
consume Ensure® were excluded (cut-off at 10% total
caloric intake).
Accumbal dopamine release following acute
presentation of palatable food
The microdialysis technique enables concentration mea-
surements of neurotransmitters in awake, freely moving
animals.Two days following surgery, wild-type and GHS-
R1A KO mice were connected to a microperfusion pump
(U-864 Syringe Pump, AgnThós AB, Lidingö, Sweden)
andperfusedwithRingersolutionatarateof 1.5 ml/min.
After1hourof habituationtothemicrodialysisperfusion
set-up, perfusion samples were collected every 20
minutes.
Four samples were collected prior to peanut butter
exposureandafurtherfoursamplesweretakenafterexpo-
sure. The average baseline was calculated from the last
three samples prior to peanut butter exposure. All of the
animals were naïve to the peanut butter and had been
allowed to consume only 1 g of chow during the dark
period prior to the dialysis experiment.The exposed tip of
the dialysis membrane (20 000 kDa cut off with an o.d./
i.d. of 310/220 mm, HOSPAL, Gambro, Lund, Sweden) of
theprobewas1 mm.Thedopaminelevelsinthedialysates
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raphy with electrochemical detection. A pump (Gyncotec
P580A; Kovalent AB; V. Frölunda, Sweden), an ion
exchange column (2.0 ¥ 100 mm, Prodigy 3 mm SA;
Skandinaviska GeneTec AB; Kungsbacka, Sweden) and a
detector (Antec Decade; Antec Leyden; Zoeterwoude, the
Netherlands) equipped with a VT-03 ﬂow cell (Antec
Leyden)wereused.Themobilephase(pH 5.6),consisting
of sulfonic acid 10 mM, citric acid 200 mM, sodium
citrate 200 mM, 10% EDTA, 30% MeOH, was vacuum
ﬁlteredusinga0.2 mmmembraneﬁlter(GHPolypro;PALL
Gelman Laboratory; Lund, Sweden). The mobile phase
wasdeliveredataﬂowrateof 0.2 ml/minpassingadegas-
ser(KovalentAB),andtheanalytewasoxidizedat+0.4 V.
Followingthemicrodialysisexperiment,themicewere
decapitated and the brains were sectioned (50 mm
thickness) and the location of the probe was determined
by microscopic observation. Only mice with probe
placement in the N.Acc. Shell were included in the statis-
tical analysis.
Conditioned place preference for palatable food
TheCPPtestwasperformedinsatiatedrats(n = 18)using
an apparatus comprised of two compartments with dis-
tinct visual and tactile cues and illuminated by 40 lux.
On day 1 (pre-test), the animals were free to explore the
entire apparatus for 10 minutes and initial preference
was scored. During the conditioning phase (day 2–6, 8,
10, 19 and 20) animals were conﬁned for 20 minutes to
one of the two compartments in the morning and to the
other compartment in the afternoon (18 sessions total).
For place conditioning, the least preferred compartment
(determinedfromthepre-test)wasalwayspairedwith5 g
of rewarding food (Ms, Marabou, Kraft Foods, Upplands
Väsby,Sweden),andtheothersidewaspairedtostandard
chow. All rats consumed the chocolate pellets during the
conditioning sessions, and rarely consumed chow. The
conditioning phase was balanced so that the conditioned
stimulus was alternated between morning and afternoon
sessions. On day 22, rats were injected (i.p.) with vehicle
(saline) or with JMV2959 (1 mg/kg) 10 minutes before
beingplacedintheCPPapparatusfor10minutes.Allrats
were habituated for 4 days to the rewarding food prior to
the pre-test and to i.p. injection on at least six occasions
prior to the test day. The behavior of the animals was
recorded with a digital camera (Canon MV900) and time
spent in each compartment was determined by visual
analysis of the video.
Acute food intake/preference measurements following
intra-VTA injections of ghrelin to mice
To investigate the acute effects of ghrelin within the VTA
on the intake and preference for palatable food, ghrelin
(2 mg total) was administered bilaterally into the VTA to
the NMRI mice. Locomotor (120 minutes) activity and
chow or peanut butter consumption (60 minutes) was
registered in eight sound attenuated, ventilated and
dimly lit locomotor boxes (420 ¥ 420 ¥ 200 mm, Kungs-
backa mät- och reglerteknik AB, Fjärås, Sweden) as pre-
viously described (Jerlhag et al. 2006). Locomotor
activity was deﬁned as the accumulated number of new
photocell beams interrupted during a 60-minute period.
On the day of the experiment, the mice were allowed to
habituate to the environment in the box for 60 minutes
beforeghrelin/vehiclechallengeandexposuretochowor
peanut butter. To reduce the inﬂuence of injection-
induced hyper-motility, the registration of locomotor
activity started 5 minutes after the last ghrelin/vehicle
administration.Themicewerenotnaïvetopeanutbutter
as they had been given free access for 1 hour everyday for
5 days prior to the study.
Measurements of food intake and food exploration
following i.c.v. ghrelin injection in VTA-lesioned rats
Food consumption and body weight gain were monitored
for 7 days following surgery in sham- and VTA-lesioned
rats. On day 8 after surgery, rats were administered
ghrelin (1 mg; i.c.v.) or vehicle and 4 hours chow con-
sumption was measured. On days 13–15 post-surgery,
the rats were administered the same treatment and were
placed in an open ﬁeld chamber containing an open
eppendorf tubeﬁlledwithpeanutbutter.Explorationtime
(deﬁned by eating or active pursuit of peanut butter, ana-
lyzed from video recordings) and peanut butter intake
overa10minutesperiodweremeasured.Priortosurgery,
the rats were familiarized with the eppendorf tube and
the palatable food for 5 days.
Statistics
Data were analyzed using Student’s t-tests, repeated-
measures two-way analysis of variance (ANOVA) or two-
way ANOVA followed by Bonferroni post hoc test. The
signiﬁcance level was P < 0.05 for all experiments. All
data are presented as means  standard error of the
mean.
RESULTS
Whenofferedafreechoicediet(chow/peanutbutter)for7
days, GHS-R1A KO mice consumed 10% less peanut
buttercomparedwithwild-typelittermatemice(P < 0.05,
Fig. 1c); chow intake and body weight did not differ
(Fig. 1a,b). In a similar free-choice paradigm (chow/
Ensure® for 10 days), JMV2959-treated rats consumed
50% less Ensure® and gained considerably less body
weight than vehicle-treated controls (both P < 0.01,
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ment (Fig. 2b). Total 7-day caloric intake (chow plus
Ensure®) was decreased in JMV2959-treated rats com-
pared with vehicle-treated rats (591  28 kcal and
839  20 kcal, respectively, P < 0.001, Student’s t-test).
Thus, vehicle-treated rats consumed 65  3% of their
total caloric intake from Ensure®; whereas, JMV2959-
treated rats consumed considerably less of their total
caloric intake (46  4%) from Ensure® (P < 0.05,
Fig. 2d). Food efﬁciency was lower in JMV2959-treated
compared with vehicle-treated rats (veh: 0.045  0.003
and JMV2959: 0.015  0.008, P < 0.05, Student’s
t-test).
In wild-type mice (n = 6) peanut butter increased the
accumbaldopaminelevelsandthiseffectwasnotobserved
in GHS-R1A KO (n = 7) mice (treatment F(1,11) = 4.91,
P < 0.05;timeF(6,66) = 0.60,P = 0.733;treatment-time
interaction F(6,66) = 2.092, P = 0.066). This difference
was largely reﬂected by the difference at the 40 minutes
time point following peanut butter presentation
(wild-type: 143  22 % from baseline, GHS-R1A KO:
80  13% from baseline, P < 0.05 Student’s t-test).
Peanut butter consumption over the 80 minutes period
was, however, not different between wild-type and GHS-
R1A KO mice (data not shown).
The chocolate pellets induced a CPP response in
vehicle- but not in JMV2959-treated rats (P < 0.001,
Fig. 3). The time spent in the rewarding food-paired
compartment was not different between vehicle- and
JMV2959-treated rats in the pre-test (Veh: 224  22
second, JMV2959: 262  19 second) and there was no
initial preference for one particular compartment in the
pre-test (51.7  4.2% versus 48.2  4.2%).
Intra-VTA administration of ghrelin to NMRI mice
increased 60 minutes locomotor activity in the presence
of either standard chow or peanut butter (both
P < 0.001, Fig. 4a). However, intra-VTA ghrelin admin-
istration increased caloric intake relative to vehicle
treatment only in mice fed with peanut butter and not in
mice fed with standard chow (P < 0.001, Fig. 4b).
Chemical lesion of the VTA in rats did not affect
body weight gain (sham: 55  3 g; lesioned: 53  3g )
or consumption of chow (sham: 140  4 g; lesioned:
138  5 g) measured over the 7 days following surgery
6
7
(a) e k a t n i   r e t t u b   t u n a e P   (c) n i a g   t h g i e w y d o B   (b) Chow intake
100
120 *
16
20
3
4
5
G
r
a
m
40
60
80
K
c
a
l
8
12
16
K
c
a
l
GHSR KO WT
0
1
2
GHSR KO WT GHSR KO WT
0
20
40
0
4
GHSR KO   
Figure 1 (a) Body weight gain; (b) chow consumption; and (c)
peanut butter consumption in growth hormone secretagogue recep-
tor 1A knockout (GHS-R1A KO) and wild-type mice offered a free
choice between ad libitum chow and peanut butter.n=8 (wild-type)
and n=5 (GHS-R1A KO), *P<0.05, Student’s t-test
Vh il
(a) Body weight gain
(b) Chow intake
50
400
**
ns
Vehicle
JMV2959 
(12 mg/kg)
20
30
40
200
300
K
c
a
l
G
r
a
m
–10
0
10
1234567
0
100
1234567
Days
Days
80
(c) Ensure intake
(d) Caloric intake (Ensure®)
600 **
40
60
c
a
l
o
r
i
c
 
i
n
t
a
k
e *
400
K
c
a
l
0
20
%
 
t
o
t
a
l
 
c
Vehicle JMV2959
0
200
1234567
Days
Figure 2 Effects of daily peripheral treat-
ment with a selective growth hormone
secretagogue receptor 1A (GHS-R1A)
antagonist (JMV2959) (12mg/kg) to rats on
(a) body weight gain; (b) cumulative chow
intake; (c) intake of Ensure
®; and (d) pref-
erence for Ensure
®. n=5–6 per group, a–c
**P<0.01, repeated-measures two-way
analysis of variance, d *P<0.05, Student’s
t-test
Ghrelin and food reward 307
© 2010 The Authors. Journal compilation © 2010 Society for the Study of Addiction Addiction Biology, 15, 304–311indicatingthatthelesiondidnotinducehypophagiaperse.
Moreover,nodifferenceinbaselinelocomotoractivitywas
found between sham and VTA-lesioned rats (702  83
and717  136beambrakes/120minutes,respectively).
I.c.v. ghrelin injection increased 4-hour standard chow
intakeinbothshamandVTA-lesionedratscomparedwith
vehicle treatment (both P < 0.001, Fig. 5a). However,
i.c.v. ghrelin-induced chow intake did not differ between
sham and VTA-lesioned rats (Fig. 5a). I.c.v. ghrelin
injection increased the consumption of peanut butter
(contained in an eppendorf tube) in both sham and VTA-
lesionedratscomparedwithvehicletreatment(P < 0.001
and P < 0.01, respectively, Fig. 5b). Ghrelin-induced
peanut butter consumption was, however, attenuated in
VTA-lesioned rats compared with sham rats (P < 0.05,
Fig. 5b). The time spent exploring the peanut butter/
eppendorf setup was considerably decreased in ghrelin-
treated VTA-lesioned rats compared with ghrelin-treated
sham rats (P < 0.001, Fig. 5c).The increased exploration
time was not coupled to actual eating but rather to the
effortof tryingtoeatandaccessremainingpeanutbutter
leftatthebottomof theeppendorf tube.Whenindividuals
that did not explore/consume any of the peanut butter
were excluded, no difference in consumption of peanut
butter could be found between ghrelin-treated sham
and VTA-lesioned rats (sham ghrelin: 0.98  0.05 g;
lesioned ghrelin: 0.78  0.15 g, P = 0.2, Student’s
t-test). Importantly, the time spent exploring the peanut-
ﬁlled eppendorf (including eating) was still decreased by
52% in VTA-lesioned rats compared with sham rats
(shamghrelin;321  28 s,lesionedghrelin;154  27 s,
P < 0.01, Student’s t-test). The proportion of rats not
interested in peanut butter following ghrelin administra-
tion was greater (2/6) in the VTA-lesioned group than in
the sham group (0/5).
DISCUSSION
In the present study genetic, pharmacologic and surgical
rodent models of altered ghrelin signaling were used to
provide evidence that ghrelin action at the level of the
VTA, a key node in the mesolimbic reward circuitry, is
important for the intake of and motivation to obtain
palatable/rewarding food. When allowed a free choice
between rewarding/palatable food and standard chow,
both rats and mice spontaneously consumed a greater
proportion of their calories from the rewarding food.
However,geneticdeletionof GHS-R1Ainmice(GHS-R1A
KO)ortreatmentwithaGHS-R1Aantagonistinratsfor7
days suppressed the intake of rewarding food without
inﬂuencingchowintake.Giventhattheintakeof reward-
ing food is driven not only by the need to balance energy
expenditure but also by its rewarding properties, an
obvious interpretation of these results is that ghrelin acts
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reward systems of the brain to increase the consumption
of rewarding foods. Consistent with this hypothesis,
accumbal dopamine release, induced by rewarding food,
was absent in GHS-R1A KO mice. Moreover, direct injec-
tion of ghrelin into the VTA of mice increased the con-
sumption of rewarding food without impacting on chow
intake. By contrast, VTA-lesioned rats displayed reduced
intake of rewarding food that was accompanied by less
explorative behavior of the food following ghrelin treat-
ment compared with sham rats. Finally, we performed
a CPP study in which rats learn to associate reward
from food with a given environment. We found that the
ability of rewarding food to condition a place preference
is greatly suppressed in rats treated with a GHS-R1A
antagonist.
Although GHS-R1A KO mice consumed 10% less
rewarding food (kcal peanut butter) than wild-type mice,
this did not result in a concomitant decrease in body
weight during this 7-day test period. Clearly, 7-day
exposure to rewarding food was insufﬁcient to induce a
difference in weight gain, as predicted from previous
studies in which it took several weeks for these mice to
show resistance to diet-induced obesity (Wortley et al.
2004). In contrast to the genetic studies, pharmacologic
suppression of ghrelin signaling in adult rats, using a
GHS-R1A antagonist JMV2959, not only suppressed
intakeof rewardingfood(Ensure®)inafreechoice(chow/
Ensure®)paradigm,butalsocausedasuppressionof body
weight. The discrepancy in body weight between the
geneticandpharmacologicstudiesmostlikelyreﬂectsthe
development of compensatory mechanisms in the GHS-
R1AKOmice,mechanismsthatarenotinoperationwhen
thecentralghrelinsignalingsystemisacutelysuppressed
(over 1 week) by the GHS-R1A antagonist. This would
imply that the GHS-R1A antagonist is able to
override the homeostatic mechanisms controlling the
energy balance, possibly involving suppressed endog-
enousghrelinactionatthelevelof themesolimbicreward
system.
In support of a mesolimbic site of action of ghrelin for
increasing the intake of rewarding food, we found that
intra-VTAghrelininjectiontomiceincreasedtheintakeof
rewarding food, but not chow, during the 60 minutes
period after injection. Indeed, ghrelin injection to these
sitesincreasesaccumbaldopaminereleaseandlocomotor
activity, indicating that ghrelin activates the mesolimbic
dopamine system (Jerlhag et al. 2006, 2007, 2008). We
conﬁrmed the locomotor stimulatory activity following
intra-VTA ghrelin administration both in chow- and
peanut butter-fed mice, providing a positive control for
ghrelin’s biological effects at this dose and via this route.
Our hypothesis that ghrelin acts at the level of the
mesolimbic reward system to inﬂuence food reward is
further supported by studies showing that GHS-R1A KO
mice do not display an accumbal dopamine response
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mesolimbic dopamine system is likely to be one of the
areas showing ghrelin-induced changes in activity
followingpresentationof visualfoodcuesinhumanfunc-
tional imaging studies (Malik et al. 2008). In contrast to
the study by Naleid et al. (2005) in rats, we did not detect
an increase in chow intake 1 hour following ghrelin
administration into the VTA of mice. This may reﬂect
differences in the feeding setup used and/or species differ-
ences as our studies were performed in mice in a novel
environment (the locomotor activity boxes). Thus,
whereas i.c.v. injection of ghrelin to rodents is able to
increase intake of chow (this study; Tschöp et al. 2000;
Wren et al. 2000), qualities of the food that reﬂect its
palatable and rewarding properties appear to be impor-
tant for determining intake when ghrelin is administered
directly into the VTA.
Further evidence that central ghrelin signaling at the
levelof themesolimbicrewardsystemisimportantforthe
intake of rewarding food was sought by administering
ghrelin to rats with VTA lesion. Although a rather crude
approach, we found that the volumes and doses of exci-
totoxinusedfortheVTA-lesiondidnotaffectspontaneous
feedingorbodyweightincomparisonwithshamratsand
that i.c.v. ghrelin-induced feeding was only suppressed in
rats exposed to rewarding food (and not standard chow).
In this experiment, the rewarding food was contained
insideanopeneppendorf tubesuchthatexplorationtime
could be assessed as a measure of motivation to eat. We
foundthatVTA-lesionedratsdidnotdifferfromshamrats
in the time spent exploring the eppendorf containing
peanut butter following vehicle injection, but that
ghrelin-inducedexploratorytimewasgreatlysuppressed.
The locomotor activity of the VTA-lesioned rats was
found to be identical to that of the sham rats at baseline
indicating that the suppressed feeding response in the
VTA-lesioned rats was not a consequence of a general
suppression of locomotor activity. Collectively, these
studies suggest that ghrelin action at the level of the VTA
impacts on food intake by inﬂuencing the motivation to
eat rewarding foods.
The CPP test is commonly used to demonstrate
reward,especiallyfromaddictivedrugs,buthasalsobeen
used to demonstrate reward associated with rewarding
foods (Herzig et al. 2005). Just as shown previously for
alcohol (Jerlhag et al. 2009), the ability of rewarding
foodstoconditionaplacepreferencewasabolishedinrats
treated peripherally with a GHS-R1A antagonist. Consis-
tentwithsuppressedreward,accumbaldopaminerelease
inducedbybothalcohol(Jerlhaget al.2009)andreward-
ing food (present article) are both absent in GHS-R1A KO
mice. Collectively, these data suggest that reward from
alcohol and food are both dependent upon the central
ghrelin signaling system.
In the present article, we focused on the rewarding
properties of food that are dependent on GHS-R1A sig-
naling. It will be interesting to discover whether the
effects of ghrelin on food reward could also be inﬂuenced
by desacyl ghrelin, a biologically active form of ghrelin
that has modest orexigenic effects (when administered
centrally), that are independent of GHS-R1A (Toshinai
et al. 2006). In this context, it will also be interesting to
discover whether food reward is altered in physiological
states in which the activity of enzymes such as ghrelin-
o-actyl transferase (GOAT) are altered. GOAT increases
the acyl-/desacyl–ghrelin ratio in plasma (Yang et al.
2008),althoughitremainstobedeterminedwhetheritis
expressed centrally and whether its activity in brain is
important for food reward or other aspects of food intake.
In summary, we used a number of complementary
approaches to demonstrate the importance of the central
ghrelin signaling system at the level of the VTA for
increasing the intake of rewarding food. Taken together
with our recent observation that the central ghrelin sig-
naling system is required for drug reward (Jerlhag et al.
2009), the emerging hypothesis is that this system may
beimportantforincreasingtheincentivevalueof natural
(e.g. food) and artiﬁcial rewards (e.g. alcohol). Our dem-
onstration that the intake of rewarding food can be sup-
pressed by ghrelin antagonists suggests that suppressed
ghrelin signaling at the level of the reward system may
have therapeutic beneﬁt for suppressing the intake of
rewarding food.
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